BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: D’amelio P, Grimaldi A, Cristofaro MA, Ravazzoli M, Molinatti PA, Pescarmona GP, Isaia GC. Alendronate reduces osteoclast precursors in osteoporosis. Osteoporos Int 2010;21:1741-50. [DOI: 10.1007/s00198-009-1129-1] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 2.2] [Reference Citation Analysis]
Number Citing Articles
1 Zhu S, Häussling V, Aspera-Werz RH, Chen T, Braun B, Weng W, Histing T, Nussler AK. Bisphosphonates Reduce Smoking-Induced Osteoporotic-Like Alterations by Regulating RANKL/OPG in an Osteoblast and Osteoclast Co-Culture Model. Int J Mol Sci 2020;22:E53. [PMID: 33374546 DOI: 10.3390/ijms22010053] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
2 Sing C, Kiel DP, Hubbard RB, Lau WC, Li GH, Kung AW, Wong IC, Cheung C. Nitrogen‐Containing Bisphosphonates Are Associated With Reduced Risk of Pneumonia in Patients With Hip Fracture. J Bone Miner Res 2020;35:1676-84. [DOI: 10.1002/jbmr.4030] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
3 Liu T, Romanova S, Wang S, Hyun MA, Zhang C, Cohen SM, Singh RK, Bronich TK. Alendronate-Modified Polymeric Micelles for the Treatment of Breast Cancer Bone Metastasis. Mol Pharm 2019;16:2872-83. [PMID: 31150251 DOI: 10.1021/acs.molpharmaceut.8b01343] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
4 Pivetta E, Wassermann B, Bulian P, Steffan A, Colombatti A, Polesel J, Spessotto P. Functional osteoclastogenesis: the baseline variability in blood donor precursors is not associated with age and gender. Oncotarget 2015;6:31889-900. [PMID: 26376614 DOI: 10.18632/oncotarget.5575] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
5 Gossiel F, Hoyle C, Mccloskey E, Naylor K, Walsh J, Peel N, Eastell R. The effect of bisphosphonate treatment on osteoclast precursor cells in postmenopausal osteoporosis: The TRIO study. Bone 2016;92:94-9. [DOI: 10.1016/j.bone.2016.08.010] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
6 D’amelio P. The immune system and postmenopausal osteoporosis. Immunological Investigations 2013;42:544-54. [DOI: 10.3109/08820139.2013.822764] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
7 Rumian Ł, Wolf-Brandstetter C, Rößler S, Reczyńska K, Tiainen H, Haugen HJ, Scharnweber D, Pamuła E. Sodium alendronate loaded poly(l-lactide- co-glycolide) microparticles immobilized on ceramic scaffolds for local treatment of bone defects. Regen Biomater 2020;7:293-302. [PMID: 32523731 DOI: 10.1093/rb/rbaa012] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
8 Zhan X, Jia L, Niu Y, Qi H, Chen X, Zhang Q, Zhang J, Wang Y, Dong L, Wang C. Targeted depletion of tumour-associated macrophages by an alendronate-glucomannan conjugate for cancer immunotherapy. Biomaterials 2014;35:10046-57. [PMID: 25245263 DOI: 10.1016/j.biomaterials.2014.09.007] [Cited by in Crossref: 89] [Cited by in F6Publishing: 80] [Article Influence: 11.1] [Reference Citation Analysis]
9 Stuss M, Rieske P, Cegłowska A, Stêpień-Kłos W, Liberski PP, Brzeziańska E, Sewerynek E. Assessment of OPG/RANK/RANKL gene expression levels in peripheral blood mononuclear cells (PBMC) after treatment with strontium ranelate and ibandronate in patients with postmenopausal osteoporosis. J Clin Endocrinol Metab 2013;98:E1007-11. [PMID: 23543663 DOI: 10.1210/jc.2012-3885] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
10 Adami G. Regulation of bone mass in inflammatory diseases. Best Pract Res Clin Endocrinol Metab 2021;:101611. [PMID: 35120799 DOI: 10.1016/j.beem.2021.101611] [Reference Citation Analysis]
11 D'Amelio P, Cristofaro MA, Grimaldi A, Ravazzoli M, Pluviano F, Grosso E, Pescarmona GP, Isaia GC. The role of circulating bone cell precursors in fracture healing. Calcif Tissue Int 2010;86:463-9. [PMID: 20390407 DOI: 10.1007/s00223-010-9362-3] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 2.4] [Reference Citation Analysis]
12 Ratajczak AE, Szymczak-Tomczak A, Rychter AM, Zawada A, Dobrowolska A, Krela-Kaźmierczak I. Impact of Cigarette Smoking on the Risk of Osteoporosis in Inflammatory Bowel Diseases. J Clin Med 2021;10:1515. [PMID: 33916465 DOI: 10.3390/jcm10071515] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Vashghani Farahani MM, Masteri Farahani R, Abdollahifar MA, Ghatresaman M, Ghoreishi SK, Hajihossainlou B, Chien S, Mostafavinia A, Rezaei F, Bayat M. Effects of pentoxifylline and alendronate on fracture healing in ovariectomy-induced osteoporosis in rats. Vet Res Forum 2019;10:93-100. [PMID: 31338141 DOI: 10.30466/vrf.2018.82732.2089] [Reference Citation Analysis]
14 D'Amelio P, Tamone C, Sassi F, D'Amico L, Roato I, Patanè S, Ravazzoli M, Veneziano L, Ferracini R, Pescarmona GP, Isaia GC. Teriparatide increases the maturation of circulating osteoblast precursors. Osteoporos Int 2012;23:1245-53. [PMID: 21617993 DOI: 10.1007/s00198-011-1666-2] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
15 Martins CA, Leyhausen G, Volk J, Geurtsen W. Effects of alendronate on osteoclast formation and activity in vitro. J Endod 2015;41:45-9. [PMID: 25442070 DOI: 10.1016/j.joen.2014.07.010] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 2.6] [Reference Citation Analysis]
16 Tsubaki M, Satou T, Itoh T, Imano M, Yanae M, Kato C, Takagoshi R, Komai M, Nishida S. Bisphosphonate- and statin-induced enhancement of OPG expression and inhibition of CD9, M-CSF, and RANKL expressions via inhibition of the Ras/MEK/ERK pathway and activation of p38MAPK in mouse bone marrow stromal cell line ST2. Mol Cell Endocrinol 2012;361:219-31. [PMID: 22579611 DOI: 10.1016/j.mce.2012.05.002] [Cited by in Crossref: 42] [Cited by in F6Publishing: 37] [Article Influence: 4.2] [Reference Citation Analysis]
17 Salamanna F, Borsari V, Contartese D, Nicoli Aldini N, Fini M. Link between estrogen deficiency osteoporosis and susceptibility to bone metastases: A way towards precision medicine in cancer patients. Breast 2018;41:42-50. [PMID: 30007267 DOI: 10.1016/j.breast.2018.06.013] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
18 Kim HS, Lee JI, Yang SS, Kim BS, Kim BC, Lee J. The effect of alendronate soaking and ultraviolet treatment on bone-implant interface. Clin Oral Implants Res 2017;28:1164-72. [PMID: 27458172 DOI: 10.1111/clr.12933] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
19 Degli Esposti L, Perrone V, Sangiorgi D, Andretta M, Bartolini F, Cavaliere A, Ciaccia A, Dell'orco S, Grego S, Salzano S, Ubertazzo L, Vercellone A, Gatti D, Fassio A, Viapiana O, Rossini M, Adami G. The Use of Oral Amino-Bisphosphonates and Coronavirus Disease 2019 (COVID-19) Outcomes. J Bone Miner Res 2021. [PMID: 34405441 DOI: 10.1002/jbmr.4419] [Reference Citation Analysis]
20 Naylor KE, Bradburn M, Paggiosi MA, Gossiel F, Peel NFA, Mccloskey EV, Walsh JS, Eastell R. Effects of discontinuing oral bisphosphonate treatments for postmenopausal osteoporosis on bone turnover markers and bone density. Osteoporos Int 2018;29:1407-17. [DOI: 10.1007/s00198-018-4460-6] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 5.8] [Reference Citation Analysis]
21 Shen X, Ma P, Hu Y, Xu G, Xu K, Chen W, Ran Q, Dai L, Yu Y, Mu C, Cai K. Alendronate-loaded hydroxyapatite-TiO 2 nanotubes for improved bone formation in osteoporotic rabbits. J Mater Chem B 2016;4:1423-36. [DOI: 10.1039/c5tb01956g] [Cited by in Crossref: 47] [Cited by in F6Publishing: 8] [Article Influence: 7.8] [Reference Citation Analysis]
22 Jacome-Galarza CE, Lee SK, Lorenzo JA, Aguila HL. Parathyroid hormone regulates the distribution and osteoclastogenic potential of hematopoietic progenitors in the bone marrow. J Bone Miner Res 2011;26:1207-16. [PMID: 21611963 DOI: 10.1002/jbmr.324] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 2.3] [Reference Citation Analysis]
23 Dalbeth N, Pool B, Stewart A, Horne A, House ME, Cornish J, Reid IR. No Reduction in Circulating Preosteoclasts 18 Months after Treatment with Zoledronate: Analysis from a Randomized Placebo Controlled Trial. Calcif Tissue Int 2013;92:1-5. [DOI: 10.1007/s00223-012-9654-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
24 Ibáñez L, Alcaraz MJ, Maicas N, Guede D, Caeiro JR, Motterlini R, Ferrándiz ML. Downregulation of the inflammatory response by CORM-3 results in protective effects in a model of postmenopausal arthritis. Calcif Tissue Int 2012;91:69-80. [PMID: 22644323 DOI: 10.1007/s00223-012-9612-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
25 Mori G, D'Amelio P, Faccio R, Brunetti G. Bone-immune cell crosstalk: bone diseases. J Immunol Res 2015;2015:108451. [PMID: 26000310 DOI: 10.1155/2015/108451] [Cited by in Crossref: 43] [Cited by in F6Publishing: 32] [Article Influence: 6.1] [Reference Citation Analysis]
26 Xie J, Yuan X, Mao W, Cai H, Gao K, Lv Z, Wang H, Ma C. 99Tc-Methylene Diphosphonate Treatment is Safe and Efficacious for Osteoporosis in Postmenopausal Differentiated Thyroid Cancer Patients Undergoing TSH Suppression: A Three-Center Non-Randomized Clinical Study. CMAR 2022;Volume 14:995-1005. [DOI: 10.2147/cmar.s354471] [Reference Citation Analysis]